PASSPORT clinical trial investigating a new investigational treatment for PSP
INFORMATION FOR HEALTHCARE PROFESSIONALS ABOUT THE PASSPORT CLINICAL TRIAL FOR STUDY PARTICIPANTS WITH PROGRESSIVE SUPRANUCLEAR PALSY (PSP)
PSP can be frustrating, because there are currently no approved or disease-modifying treatments for you to offer patients. One new option you may want to consider discussing with your patients is enrollment into the PASSPORT clinical trial. This is a phase 2b trial designed to evaluate the effectiveness and safety of an investigational study drug in PSP study participants.
PSP is a rare, tau-based neurodegenerative disorder. The investigational study drug is an antibody which sticks to toxic tau and helps remove it from the space between the cells of the brain. It may prevent the spreading of toxic tau to normal cells.
We’re looking to recruit approximately 396 adults from various countries aged between 41 and 86 with PSP who:
- Can walk at least 10 steps either independently or with assistance
- Have a reliable caregiver who can attend all clinical trial visits
- Are not living in a nursing facility or dementia care facility
The main clinical trial lasts just over a year. It is divided into a 6-week screening period and a 52-week double-blind dosing period, when either the investigational study drug or inactive substance (placebo) is given, with clinic visits approximately every 4 weeks. Once this portion of the clinical trial concludes, there will also be an opportunity to participate in an open-label dosing period.
All clinical trial-related medications, tests and assessments will be given to participants at no cost. Reimbursement for travel and other clinical trial-related expenses may be available.